Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Evans

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Antimicrobial Agents and Chemotherapy|July 16, 2024
A phase 1 open label study to assess the human mass balance and metabolite profile of <sup>14</sup>C-fosmanogepix, a novel Gwt-1 inhibitor in healthy male participantsMichael R Hodges, Eric Ople, Philip Evans, et al.
The British Journal of Radiology|September 5, 2017
Clinical applications of textural analysis in non-small cell lung cancerIain Phillips, Mazhar Ajaz, Veni Ezhil, et al.
Biopharmaceutics & Drug Disposition|June 11, 2011
Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasibleMicaela B Reddy, Alyson Connor, Barbara J Brennan, et al.
Therapeutic Innovation & Regulatory Science|September 21, 2018
Novel Gastroretentive Controlled Release Formulations for Once-Daily Administration: Assessment of Clinical Feasibility and Formulation Concept for RaltegravirRajesh Krishna, Matthew L Rizk, Patrick J Larson, et al.
The International Journal of Behavioral Nutrition and Physical Activity|January 17, 2015
Waste the waist: a pilot randomised controlled trial of a primary care based intervention to support lifestyle change in people with high cardiovascular riskColin Greaves, Fiona Gillison, Afroditi Stathi, et al.
Archives of Disease in Childhood|June 26, 2024
General population screening for type 1 diabetes using islet autoantibodies at the preschool vaccination visit: a proof-of-concept study (the T1Early study)Claire Scudder, Julia Townson, Jane Bowen-Morris, et al.
Health Technology Assessment (Winchester, England)|April 14, 2018
Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCTSimon J Griffin, M Angelyn Bethel, Rury R Holman, et al.
BMC Nephrology|December 8, 2020
Safely reducing haemodialysis frequency during the COVID-19 pandemicMichelle Da Silva Lodge, Thilini Abeygunaratne, Helen Alderson, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|January 16, 2024
Cost-utility analysis of molnupiravir for high-risk, community-based adults with COVID-19: an economic evaluation of the PANORAMIC trialMay Ee Png, Victoria Harris, Jenna Grabey, et al.
The Lancet. Infectious Diseases|September 12, 2024
Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trialVictoria Harris, Jane Holmes, Oghenekome Gbinigie-Thompson, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Antimicrobial Agents and Chemotherapy|July 16, 2024
A phase 1 open label study to assess the human mass balance and metabolite profile of <sup>14</sup>C-fosmanogepix, a novel Gwt-1 inhibitor in healthy male participantsMichael R Hodges, Eric Ople, Philip Evans, et al.
The British Journal of Radiology|September 5, 2017
Clinical applications of textural analysis in non-small cell lung cancerIain Phillips, Mazhar Ajaz, Veni Ezhil, et al.
Biopharmaceutics & Drug Disposition|June 11, 2011
Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasibleMicaela B Reddy, Alyson Connor, Barbara J Brennan, et al.
Therapeutic Innovation & Regulatory Science|September 21, 2018
Novel Gastroretentive Controlled Release Formulations for Once-Daily Administration: Assessment of Clinical Feasibility and Formulation Concept for RaltegravirRajesh Krishna, Matthew L Rizk, Patrick J Larson, et al.
The International Journal of Behavioral Nutrition and Physical Activity|January 17, 2015
Waste the waist: a pilot randomised controlled trial of a primary care based intervention to support lifestyle change in people with high cardiovascular riskColin Greaves, Fiona Gillison, Afroditi Stathi, et al.
Archives of Disease in Childhood|June 26, 2024
General population screening for type 1 diabetes using islet autoantibodies at the preschool vaccination visit: a proof-of-concept study (the T1Early study)Claire Scudder, Julia Townson, Jane Bowen-Morris, et al.
Health Technology Assessment (Winchester, England)|April 14, 2018
Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCTSimon J Griffin, M Angelyn Bethel, Rury R Holman, et al.
BMC Nephrology|December 8, 2020
Safely reducing haemodialysis frequency during the COVID-19 pandemicMichelle Da Silva Lodge, Thilini Abeygunaratne, Helen Alderson, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|January 16, 2024
Cost-utility analysis of molnupiravir for high-risk, community-based adults with COVID-19: an economic evaluation of the PANORAMIC trialMay Ee Png, Victoria Harris, Jenna Grabey, et al.
The Lancet. Infectious Diseases|September 12, 2024
Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trialVictoria Harris, Jane Holmes, Oghenekome Gbinigie-Thompson, et al.
Pageof 8